In this free webinar, gain insights into selecting and validating digital endpoints in early and mid-phase studies, including what makes an endpoint scientificallyIn this free webinar, gain insights into selecting and validating digital endpoints in early and mid-phase studies, including what makes an endpoint scientifically

Novel Digital Endpoint Solutions for Early and Mid-Phase Development, Upcoming Webinar Hosted by Xtalks

2026/02/18 21:46
3 min read

In this free webinar, gain insights into selecting and validating digital endpoints in early and mid-phase studies, including what makes an endpoint scientifically robust, feasible and appropriate for early phase development. Attendees will learn how early-phase studies are used to refine endpoints and assess feasibility. The featured speakers will share operational considerations for implementing digital endpoints across sites and CROs, including site readiness, training, data quality and managing added complexity. Attendees will understand how to design endpoints for continuity from early development into Phase III, including how to minimize rework by building for scalability, reproducibility and regulatory acceptance. The speakers will discuss the role of imaging and patient-reported outcomes in early oncology development, mentioning when and why these measures add value for dose optimization, safety and early efficacy signaling.

TORONTO, Feb. 18, 2026 /PRNewswire/ — Leveraging Australia’s Early-Phase Advantages to Set Up Scalable, Late-Phase Global Success

Early and mid-phase trials are where critical development decisions are made, yet many programs still rely on endpoints that are hard to scale, justify or operationalize globally.

In this webinar, Clario‘s scientific and operational experts are joined by Tina Soulis, Founder and Director of Alithia Life Sciences, who brings a regional perspective from Australia’s early-phase clinical trial ecosystem. Together, they’ll explore how digital endpoints, including eCOA, medical imaging and cardiac testing, can be implemented early in development to generate stronger evidence, reduce variability and support regulatory engagement.

Using Australia as a practical example, the session shows how early digital strategies can lay a scalable foundation for global later phase success.

Register for this webinar to learn how a digital endpoint strategy implemented in early and mid-phase development can strengthen evidence generation and support regulatory confidence.

Join Todd Rudo (Moderator), MD, EVP, Chief Medical Officer, Clario; Tina Soulis, Founder and Director, Alithia Life Sciences; Kelly Dumais, PhD, Senior Director and Global Head of eCOA Science and Consulting, Clario; and Anu Bansal, MD, MS, VP Medical Imaging, Oncology, Clario, for the live webinar on Tuesday, March 10, 2026, at 11am AEDT/Australia-Eastern (Monday, March 9, 2026 at 8pm EST/N. America).

For more information, or to register for this event, visit Novel Digital Endpoint Solutions for Early and Mid-Phase Development.

ABOUT XTALKS

Xtalks — The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.

Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what’s next.

To learn more about Xtalks, visit www.xtalks.com
For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us

Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/novel-digital-endpoint-solutions-for-early-and-mid-phase-development-upcoming-webinar-hosted-by-xtalks-302691170.html

SOURCE Xtalks

Market Opportunity
FreeRossDAO Logo
FreeRossDAO Price(FREE)
$0.00005893
$0.00005893$0.00005893
+1.25%
USD
FreeRossDAO (FREE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Trump adviser demands Fed economists be 'disciplined' for arguing with presidential tactic

Trump adviser demands Fed economists be 'disciplined' for arguing with presidential tactic

President Donald Trump's longtime economic adviser Kevin Hassett suggested on CNBC Wednesday that the economists at the New York Fed who produced an analysis revealing
Share
Rawstory2026/02/18 22:59
Trump admin appeals after judge orders slavery exhibit returned to Philadelphia museum

Trump admin appeals after judge orders slavery exhibit returned to Philadelphia museum

President Donald Trump's Department of the Interior and its secretary, Doug Burgum, have appealed after Judge Cynthia Rufe invoked George Orwell's dystopian novel
Share
Rawstory2026/02/18 23:24
BlackRock boosts AI and US equity exposure in $185 billion models

BlackRock boosts AI and US equity exposure in $185 billion models

The post BlackRock boosts AI and US equity exposure in $185 billion models appeared on BitcoinEthereumNews.com. BlackRock is steering $185 billion worth of model portfolios deeper into US stocks and artificial intelligence. The decision came this week as the asset manager adjusted its entire model suite, increasing its equity allocation and dumping exposure to international developed markets. The firm now sits 2% overweight on stocks, after money moved between several of its biggest exchange-traded funds. This wasn’t a slow shuffle. Billions flowed across multiple ETFs on Tuesday as BlackRock executed the realignment. The iShares S&P 100 ETF (OEF) alone brought in $3.4 billion, the largest single-day haul in its history. The iShares Core S&P 500 ETF (IVV) collected $2.3 billion, while the iShares US Equity Factor Rotation Active ETF (DYNF) added nearly $2 billion. The rebalancing triggered swift inflows and outflows that realigned investor exposure on the back of performance data and macroeconomic outlooks. BlackRock raises equities on strong US earnings The model updates come as BlackRock backs the rally in American stocks, fueled by strong earnings and optimism around rate cuts. In an investment letter obtained by Bloomberg, the firm said US companies have delivered 11% earnings growth since the third quarter of 2024. Meanwhile, earnings across other developed markets barely touched 2%. That gap helped push the decision to drop international holdings in favor of American ones. Michael Gates, lead portfolio manager for BlackRock’s Target Allocation ETF model portfolio suite, said the US market is the only one showing consistency in sales growth, profit delivery, and revisions in analyst forecasts. “The US equity market continues to stand alone in terms of earnings delivery, sales growth and sustainable trends in analyst estimates and revisions,” Michael wrote. He added that non-US developed markets lagged far behind, especially when it came to sales. This week’s changes reflect that position. The move was made ahead of the Federal…
Share
BitcoinEthereumNews2025/09/18 01:44